RegenHU
Provider of advanced bioprinting platforms, including hardware (R-GEN series) and software (SHAPER), for tissue engineering, drug discovery, and personalized medicine.
- CEO / Founder
- Simon MacKenzie
- Team Size
- 11-50
- Stage
- Commercial Stage
- Total Funding
- $24.6K
- Latest Round
- Grant
- Key Investors
- Nivalis Group (Primary Backer), Eurostars Programme, Venture Kick
Technology & Products
Key Products
["R-GEN 100 Bioprinter","R-GEN 200 Bioprinter","SHAPER Software","Various print heads and accessories"]
Technological Advantage
The company's key advantage is its multi-material and multi-technology platforms that can be customized for specific research needs. This versatility allows for the precise fabrication of complex biological structures, accelerating R&D in tissue engineering, drug screening, and personalized medicine.
Differentiation
Value Proposition
To enable researchers and clinicians to achieve their goals in regenerative medicine and drug discovery through cutting-edge, customizable, and user-friendly bioprinting technologies that deliver accuracy and repeatability.
How They Differentiate
RegenHU differentiates through its high-precision, modular, and complete bioprinting solutions (hardware, software, and services). Its strong European presence and reputation for Swiss engineering quality set it apart. The company focuses on providing a versatile platform adaptable to a wide range of research applications.
Market & Competition
Target Customers
Biotech, pharmaceutical, cosmetics, and MedTech industries, as well as leading universities and research institutions.
Industry Verticals
["Biotechnology","Pharmaceutical","Cosmetics","Medical Research"]
Competitors
BICO (formerly CELLINK); Organovo; Aspect Biosystems
Growth & Milestones
Growth Metrics
Privately held, specific growth metrics are not public. The company reports a growing global partnership network and instrument installation in 38 countries.
Major Milestones
["2007: Company founded by Marc Thurner.","2011: Secured backing from the Nivalis Group.","2019: Simon MacKenzie appointed as CEO.","Launch of the next-generation R-GEN bioprinter series and SHAPER software.","Expansion with an office in the United States.","2022: Granted new patents for advanced bioprinting technology."]
Notable Customers
Rice University (Biomaterials Lab)